Drug Type ASO |
Synonyms- |
Target |
Mechanism NLRP1 inhibitors(NLR family pyrin domain containing 1 inhibitors), NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Molecular AxiomStartup |
Active Organization Molecular AxiomStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neurodegenerative Diseases | Preclinical | - | Molecular AxiomStartup | 02 Mar 2023 |